Roivant Sciences SEC Filings

Roivant Sciences Ltd. CFO Richard Pulik reported a tax-withholding share disposition related to restricted stock units (RSUs). On this event, 18,962 common shares were withheld at a value of $32.41 per share to cover tax obligations triggered by the vesting and settlement of previously granted RSUs. After this non‑market transaction, Pulik directly holds 278,549 common shares, indicating he retains a substantial equity position in the company.

Roivant Sciences Ltd. submitted a Form 144 disclosing a proposed sale of 200,000 common shares tied to an Options Exercise - Grant Date 05/22/2026. The filing lists a sale date of 05/22/2026 for those shares.

The filing also records recent sales by Eric Venker: 7,051 common shares on 02/20/2026 for $191,434.65, 200,000 common shares on 03/17/2026 for $5,648,836.44, and 200,000 common shares on 04/20/2026 for $5,917,134.05.

Roivant Sciences Ltd. outlines a broad late-stage biopharmaceutical pipeline focused on autoimmune and cardiopulmonary diseases, alongside key ownership stakes in multiple "Vants." Lead asset brepocitinib is under FDA Priority Review for dermatomyositis with a PDUFA target in the third quarter of 2026, and in Phase 3 trials for several inflammatory indications.

Immunovant is advancing IMVT-1402, a potentially best-in-class FcRn inhibitor in multiple potentially registrational studies, while discontinuing first‑generation batoclimab to concentrate resources on IMVT‑1402. Pulmovant is developing once‑daily inhaled mosliciguat for pulmonary hypertension associated with interstitial lung disease in a global Phase 2 trial.

Roivant also highlights Genevant, a majority‑owned nucleic acid delivery company whose LNP technology underpins the first FDA‑approved systemic RNA‑LNP drug and which entered a $2.25 billion global settlement with Moderna in March 2026, including $950 million due by July 2026 and a further $1.3 billion contingent on a favorable appeal ruling.

Roivant Sciences Ltd. reported fourth-quarter and full-year results for the period ended March 31, 2026, and outlined key pipeline and legal milestones. For the quarter, income from continuing operations was $355.7 million, driven largely by a $770.2 million gain from a global litigation settlement with Moderna.

For the full year, Roivant posted a $397.9 million loss from continuing operations and a non-GAAP loss of $747.7 million, reflecting heavy investment in R&D and share-based compensation. The company held $4.3 billion in cash, cash equivalents and marketable securities as of March 31, 2026, which it states supports a cash runway into profitability.

Operationally, Roivant highlighted strong preliminary IMVT-1402 data in difficult-to-treat rheumatoid arthritis, FDA Priority Review for brepocitinib in dermatomyositis, Breakthrough Therapy Designation in cutaneous sarcoidosis and rapid enrollment for mosliciguat in pulmonary hypertension associated with interstitial lung disease. The Moderna settlement totals $2.25 billion, including a $950 million non-contingent payment due in July 2026 and a contingent $1.3 billion payment tied to a Section 1498 appeal outcome.

Roivant Sciences Ltd. ownership update: Morgan Stanley and Morgan Stanley Investment Management Inc. file an amended Schedule 13G/A reporting beneficial ownership stakes in Roivant common shares. The filing shows 6.9% of the class (Morgan Stanley) and 6.7% (MSIM) with shared voting and dispositive powers disclosed.

The filing attributes specific shared voting power and shared dispositive power amounts to the reporting entities and states the submission is made on behalf of certain operating units collectively described as the "MS Reporting Units." Signature blocks and exhibits (Joint Filing Agreement; Item 7 information) are included.

Roivant Sciences Ltd. ownership amendment: Vivek Ramaswamy reports beneficial ownership of 25,534,970 common shares, representing 3.6% of the outstanding common shares. The percentage is calculated using 715,701,137 shares outstanding as of February 2, 2026. The filing is an Amendment No. 7 to a Schedule 13G/A and is signed by an attorney-in-fact on behalf of Mr. Ramaswamy.

Roivant Sciences Ltd. president and Immunovant CEO Eric Venker reported an exercise-and-sale transaction in the company’s common shares. He exercised stock options to acquire 200,000 common shares at $3.85 per share and sold 200,000 common shares in open-market transactions at a weighted average price of $29.59 per share, with individual trade prices ranging from $29.33 to $29.88. Following these transactions, he directly holds 1,647,546 common shares. A related stock option award to purchase common shares is described as fully vested.

Pulik Richard reported acquisition or exercise transactions in this Form 4 filing.

Roivant Sciences CFO Richard Pulik received equity compensation on April 20, 2026. He was granted 60,644 Common Shares as restricted stock units and now holds 297,511 Common Shares directly. He also received 84,026 stock options to buy Common Shares at $29.08 per share, expiring in 2036.

The RSUs vest 25% one year after April 20, 2026, with the rest in twelve equal quarterly installments. The options vest 25% one year after that date, then in thirty-six equal monthly installments, all subject to his continued service.

Roivant Sciences Ltd. reported a compensation-related equity grant to Chief Accounting Officer Jennifer Humes. She received 29,173 Common Share RSUs, bringing her direct Common Share holdings to 113,364 shares after the award.

Humes was also granted 27,157 stock options to buy Common Shares at an exercise price of $29.08 per share, expiring on April 19, 2036. Both the RSUs and options have a vesting commencement date of April 20, 2026 and vest over time, subject to her continuous service with the company.